OXY-5-1

........10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250.......260.......270.......280.......... MLKSSWRKTALMAAAVPLLLASGSLWASADAIQQKLADLEKHSGGRLGVALINTADDSQTLYRGDERFAMCSTGKVMAAAAVLKQSESNPEVVNKRLEIKKADLVVWSPITEKHLQSGMTLAELSAAALQYSDNTAMNKIIGYLGGPEKVTAFAQSIGDVTFRLDRMEPALNSAIPGDKRDTTTPLAMAESLRKLTLGNALGEQQRAQLVTWLKGNTTGGQSIRAGLPASWAVGDKTGAGDYGTTNDIAVIWPENHAPLVLVTYFTQPQQDAKSRKEVLAAAAKIVTEGL

OXY-5-2	.........................................R................................................................................................................L.......................................................................................................................................	99.31 %
OXY-5-3	.........................................R....................................................................................................................................................................T...................................................................................	99.31 %
OXY-5-4	................................H........R.......................................................................Y............................................................................................T...................................................................................	98.62 %
OXY-5-5	.........................................R........................................................................................................................................................................................................................................................	99.66 %
OXY-5-6	.........................................R........................................................................................................................................E...............................................................................................................	99.31 %
OXY-5-7	.........................................R...........................................................S.................................................................................................................................V..........................................................	98.97 %
OXY-5-8	.........................................R................................................................................................................L...................................................T...................................................................................	98.97 %
OXY-5-9	..............................................................................................................................................................................................................T...................................................................................	99.66 %
OXY-5-10	.........................................R...................................V................................................................................................................................T...................................................................................	98.97 %
OXY-5-11	.........................................R..............N.........................................................................................................................................................................................................................................	99.31 %

Last updated: November 20, 2024.

If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.

The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).

Contact: contact@bldb.eu

Live statistics (since December 3rd, 2023)